QRG Capital Management Inc. Trims Position in Merck & Co., Inc. $MRK

by · The Cerbat Gem

QRG Capital Management Inc. lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 14.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 428,993 shares of the company’s stock after selling 70,739 shares during the period. QRG Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $55,126,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Bullseye Investment Management LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $27,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $26,000. Graney & King LLC lifted its holdings in shares of Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after acquiring an additional 200 shares during the last quarter. Montgomery Financial Services LLC bought a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $41,000. Finally, Evergreen Advisors LLC bought a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $43,000. Institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In related news, EVP David Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last ninety days. Corporate insiders own 0.17% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

  • Positive Sentiment: Pipeline catalysts could drive a re-rating. Bank of America maintained its Buy rating after meetings with Merck’s chief medical officer, citing multiple potential oncology and other clinical readouts over the next 12–18 months. Positive data could improve confidence in Merck’s post-KEYTRUDA growth outlook. Merck pipeline seen driving potential re-rating as clinical catalysts approach
  • Positive Sentiment: WINREVAIR received a meaningful U.S. label expansion. The FDA approved updated labeling incorporating Phase 3 HYPERION data for recently diagnosed adults with pulmonary arterial hypertension. The change broadens the therapy’s supported clinical use and may strengthen WINREVAIR’s contribution to Merck’s growth. FDA approves WINREVAIR label update
  • Positive Sentiment: Japan approved subcutaneous KEYTRUDA QLEX. The formulation gives patients and clinicians an alternative to intravenous administration across existing local indications, potentially improving convenience and supporting KEYTRUDA’s commercial durability in an important market. Japan clears new KEYTRUDA dosing option
  • Neutral Sentiment: Analyst coverage remains broadly favorable, with Merck carrying an average Buy-equivalent recommendation. However, the stock’s elevated valuation means positive ratings may already reflect considerable optimism. Wall Street analysts assess Merck
  • Negative Sentiment: Profit-taking risk is rising. Merck has substantially outperformed the broader market over the past year, prompting concerns that the rally has outpaced near-term fundamentals. A valuation near 118 times earnings could leave MRK vulnerable if clinical results disappoint or pipeline progress is delayed. Merck’s rally and profit-taking risks

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Scotiabank boosted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. CICC Research started coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective for the company. Morgan Stanley upgraded Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $116.00 to $179.00 in a report on Thursday, August 20th. Leerink Partners boosted their target price on Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Finally, Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. Seventeen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $154.24.

View Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Down 1.9%

MRK traded down $2.84 on Wednesday, reaching $148.07. 9,631,266 shares of the company traded hands, compared to its average volume of 10,787,158. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $156.92. The firm has a fifty day simple moving average of $139.57 and a two-hundred day simple moving average of $125.66. The company has a market cap of $365.31 billion, a P/E ratio of 118.46, a price-to-earnings-growth ratio of 6.51 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).